These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3598607)

  • 1. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
    Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
    J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA; Krivit W; Chard RL; Hammond D
    Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
    Rivera G; Green A; Hayes A; Avery T; Pratt C
    Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of high-dose teniposide.
    Holthuis JJ; de Vries LG; Postmus PE; van Oort WW; Verleun H; Hulshoff A; Sleijfer DT; Mulder NH
    Cancer Treat Rep; 1987 Jun; 71(6):599-603. PubMed ID: 3581097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).
    Canal P; Bugat R; Chatelut E; Pinel MC; Houin G; Plusquellec Y; Carton M
    Eur J Cancer Clin Oncol; 1989 May; 25(5):815-20. PubMed ID: 2737218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
    Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
    Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
    Hayes FA; Abromowitch M; Green AA
    Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.
    Rodman JH; Furman WL; Sunderland M; Rivera G; Evans WE
    J Clin Oncol; 1993 Feb; 11(2):287-93. PubMed ID: 8426206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
    Rodman JH; Sunderland M; Kavanagh RL; Ochs J; Yalowich J; Evans WE; Rivera GK
    Cancer Res; 1990 Jul; 50(14):4267-71. PubMed ID: 2194652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
    Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teniposide (VM26) disposition in children with leukemia.
    Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
    Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Given FT; Stehman FB
    Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teniposide is not effective in chronic lymphocytic leukemia.
    Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
    Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teniposide: a review of 12 years of experience.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
    Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of teniposide in advanced breast cancer.
    Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
    Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of teniposide (VM-26) in multiple myeloma.
    Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
    Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.